Company
CNSX:MSET
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
65 stories · page 4 of 4
MSP-1014 demonstrated “superior efficacy” and an improved safety profile compared to generic psilocybin in a head-to-head clinical trial
The analyst noted the company is building out next-generation psychedelics with four families of compounds including psilocybin and DMT/5-MeO-DMT analogues as well as a fifth family platform technology for improving psychedelic drugs
Archive
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The program aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT
The differentiated psilocybin-based compound will move forward into current GMP-compliant manufacturing and IND-enabling studies
